Log in

goodpods headphones icon

To access all our features

Open the Goodpods app
Close icon
The Neuroendocrine Cancer Foundation Podcast - Top 10 FAQs with neuroendocrine cancer experts - Episode 27: What to Know About Neuroendocrine Tumor Liver Metastases

Episode 27: What to Know About Neuroendocrine Tumor Liver Metastases

11/15/23 • 46 min

The Neuroendocrine Cancer Foundation Podcast - Top 10 FAQs with neuroendocrine cancer experts

What do you call NETs in the liver? How often do NETs spread? What causes NETs to spread? How do you determine if surgery is an option? Dr. Xavier Keutgen from University of Chicago brings clarity to NET tumors found in the liver and describes how surgery fits in with other treatments for metastatic NETs.

ABOUT DR. XAVIER KEUTGEN

Xavier M. Keutgen MD is a board-certified, double-fellowship trained surgeon who specializes in the treatment of gastro-entero-pancreatic neuroendocrine tumors and neoplasms of the thyroid-, parathyroid- and adrenal glands. A native from Belgium, Dr. Keutgen graduated magna cum laude from the University of Heidelberg Medical School in Germany and completed a general surgery residency and surgical oncology research fellowship at New York Presbyterian Hospital-Weill Cornell Medical Center. He then completed a hepato-pancreato-biliary fellowship at the University Hospital of Zurich in Switzerland as well as an endocrine oncology and surgery fellowship at the National Cancer Institute, National Institutes of Health (NIH) in Bethesda, Maryland. Dr. Keutgen currently serves as the director of the Neuroendocrine Tumor Program, director of the Endocrine Research Program and co-director of the Von Hippel-Lindau Clinical Care Program at the University of Chicago Medicine.

Throughout his career Dr. Keutgen has developed a particular interest in clinical, translational and basic science research. His laboratory specializes in investigating the role of radiation therapy and DNA damage repair in pancreatic, lung and small bowel neuroendocrine tumors, discovering new actionable molecular targets for neuroendocrine tumors, and elucidating new mechanisms of drug delivery for endocrine malignancies.
TOP TEN QUESTIONS

  1. What is liver NETs? How often do NETs spread? Is it expected that NETs will eventually spread?
  2. If the primary tumor was already removed, do you now call this liver NET or do you still refer to it by the primary site of origin – and why? How is this different from liver cancer?
  3. What causes NETs to spread? Is there anything that is done to cause NET tumors to spread? Is there anything that can be done to keep them from spreading?
  4. How do you determine if surgery is an option? What is involved in evaluating metastases? What scans or labs are needed?
  5. How do you decide what the “tumor burden” is?
  6. How do you weigh the grade or ki67? How do you weigh tumor size? Is there a cut-off for tumor size or the number of tumors that is too much to operate?
  7. How does one decide between surgery versus other options? How often can surgery or other treatments be done? How safe is liver surgery?
  8. How do you approach surgery for someone with liver tumors who also has tumors in the tail versus the head of the pancreas?
  9. When someone has had a Whipple surgery and later is found to have tumors in the liver, what are the options?
  10. What advances in the field are you most excited about?

For more information, visit LACNETS.org.

plus icon
bookmark

What do you call NETs in the liver? How often do NETs spread? What causes NETs to spread? How do you determine if surgery is an option? Dr. Xavier Keutgen from University of Chicago brings clarity to NET tumors found in the liver and describes how surgery fits in with other treatments for metastatic NETs.

ABOUT DR. XAVIER KEUTGEN

Xavier M. Keutgen MD is a board-certified, double-fellowship trained surgeon who specializes in the treatment of gastro-entero-pancreatic neuroendocrine tumors and neoplasms of the thyroid-, parathyroid- and adrenal glands. A native from Belgium, Dr. Keutgen graduated magna cum laude from the University of Heidelberg Medical School in Germany and completed a general surgery residency and surgical oncology research fellowship at New York Presbyterian Hospital-Weill Cornell Medical Center. He then completed a hepato-pancreato-biliary fellowship at the University Hospital of Zurich in Switzerland as well as an endocrine oncology and surgery fellowship at the National Cancer Institute, National Institutes of Health (NIH) in Bethesda, Maryland. Dr. Keutgen currently serves as the director of the Neuroendocrine Tumor Program, director of the Endocrine Research Program and co-director of the Von Hippel-Lindau Clinical Care Program at the University of Chicago Medicine.

Throughout his career Dr. Keutgen has developed a particular interest in clinical, translational and basic science research. His laboratory specializes in investigating the role of radiation therapy and DNA damage repair in pancreatic, lung and small bowel neuroendocrine tumors, discovering new actionable molecular targets for neuroendocrine tumors, and elucidating new mechanisms of drug delivery for endocrine malignancies.
TOP TEN QUESTIONS

  1. What is liver NETs? How often do NETs spread? Is it expected that NETs will eventually spread?
  2. If the primary tumor was already removed, do you now call this liver NET or do you still refer to it by the primary site of origin – and why? How is this different from liver cancer?
  3. What causes NETs to spread? Is there anything that is done to cause NET tumors to spread? Is there anything that can be done to keep them from spreading?
  4. How do you determine if surgery is an option? What is involved in evaluating metastases? What scans or labs are needed?
  5. How do you decide what the “tumor burden” is?
  6. How do you weigh the grade or ki67? How do you weigh tumor size? Is there a cut-off for tumor size or the number of tumors that is too much to operate?
  7. How does one decide between surgery versus other options? How often can surgery or other treatments be done? How safe is liver surgery?
  8. How do you approach surgery for someone with liver tumors who also has tumors in the tail versus the head of the pancreas?
  9. When someone has had a Whipple surgery and later is found to have tumors in the liver, what are the options?
  10. What advances in the field are you most excited about?

For more information, visit LACNETS.org.

Previous Episode

undefined - Episode 26: What to Know About Lung NETs

Episode 26: What to Know About Lung NETs

What are lung NETs? What is DIPNECH? How is lung NET similar or different from lung cancer? Dr. Vineeth Sukrithan from Ohio State University Comprehensive Cancer Center gives a comprehensive overview of lung NET and DIPNECH, including the work-up and treatment options. He also discusses open clinical trials and exciting advances in lung NET research on the horizon.
For more information, visit LACNETS.org/podcast/24.

For more information, visit LACNETS.org.

For more information, visit LACNETS.org.

Next Episode

undefined - Top 10 Highlights of 2023 NANETS Symposium

Top 10 Highlights of 2023 NANETS Symposium

In this special episode, Oregon Health & Sciences University (OHSU) Medical oncologist, Dr. Guillaume (Will) Pegna, recaps the North American Neuroendocrine Tumor Society (NANETS) 2023 Multidisciplinary NET Medical Symposium. He shares the latest developments in NET research and medical advances from the conference and discusses why they matter to the NET patient community.
MEET DR. GUILLAUME PEGNA
Dr. Pegna is a medical oncologist who specializes in the care of adults with neuroendocrine tumors (NETs). He is additionally interested and experienced in the management of rare tumors including pheochromocytomas, paragangliomas, and adrenocortical carcinomas as well as other gastrointestinal cancers.

Dr. Pegna is actively involved with clinical trials and cancer research to improve survival and quality of life for cancer patients and to better understand the biology of these diseases. He specializes in the use of chemotherapy, immunotherapy, and multidisciplinary approaches to cancer care. Dr. Pegna finds it rewarding to help patients understand their disease, providing treatment options based on each individual patient, and supporting them through their treatment journeys.
For more information, visit LACNETS.org/podcast/28

For more information, visit LACNETS.org.

Episode Comments

Generate a badge

Get a badge for your website that links back to this episode

Select type & size
Open dropdown icon
share badge image

<a href="https://goodpods.com/podcasts/the-neuroendocrine-cancer-foundation-podcast-top-10-faqs-with-neuroend-451284/episode-27-what-to-know-about-neuroendocrine-tumor-liver-metastases-61470111"> <img src="https://storage.googleapis.com/goodpods-images-bucket/badges/generic-badge-1.svg" alt="listen to episode 27: what to know about neuroendocrine tumor liver metastases on goodpods" style="width: 225px" /> </a>

Copy